Diabetic Retinopathy Market Size Growth Expects Significant Thrust at a CAGR of 3% During the Study Period, 2018-30 in the 7MM | DelveInsight - Seite 2

Diabetic Retinopathy: Disease Overview 

Diabetic Retinopathy is a significant complication of diabetes mellitus, which is a leading cause of visual loss in working-age populations. With an increasing prevalence of diabetes, it appears that the prevalence of Diabetic Retinopathy is also on the rise. Type 2 diabetes, which is becoming more common, leads to over 60% of patients diagnosing with Diabetic Retinopathy within the first 20 years of onset. 

Furthermore, Age is a noteworthy risk factor for Diabetic Retinopathy prevalence as the chances increase with the age. 

Diabetic Retinopathy Epidemiology Segmentation 

Diabetic Retinopathy Market and Epidemiology Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

• Total Diagnosed Diabetic Retinopathy Prevalent Cases 
• Gender-Specific Diabetic Retinopathy Cases
• Age-Specific Diabetic Retinopathy Cases
• Severity-Specific  Diabetic Retinopathy Cases

The report proffers a holistic view of the present Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market's hidden potential, and plans strategically to handle market risks.

For a comprehensive analysis, visit Diabetic Retinopathy Epidemiological Analysis and Changing Trends 

Diabetic Retinopathy Therapy Market 

The present scenario in the Diabetic Retinopathy therapeutic landscape appears quite confined, limited to laser treatment, eye injections, and anti-VEGF drugs, which are the preferred first line of therapy. The treatments for DR relies heavily on the presence of macular edema.

Available anti-VEGF drugs include aflibercept (Eylea from Regeneron and Bayer), ranibizumab (Lucentis from Genentech and Novartis), and bevacizumab (Avastin from Genentech) that are presently enjoying the monopoly in the Diabetic Retinopathy market.

However, there exist several gaps in the Diabetic Retinopathy therapeutic market in the form of an absence of biomarkers, a lack of technologies that are potential enough to predict the disease course in patients, and novel pathways to offer novel treatments. 

Reach out to us @ Diabetic Retinopathy Marketed Therapies for more information on available treatment regimens 

Diabetic Retinopathy Market